Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men with Castration Resistant Nonmetastatic Prostate Cancer

Researchers at the Department of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts performed an evaluation of the natural history of castration-resistant non-metastatic prostate cancer.

For their analysis, the researchers used data from 331 subjects in a placebo group of a randomized controlled trial to evaluate the relations of disease and host characteristics with time to first bone metastases (met) in men with prostate cancer, rising prostate-specific antigen (PSA) despite androgen deprivation therapy, and no radiographic evidence of metastases.

Relations between baseline covariates a